bluuebunny/crossref_metadata_2025_split huggingface dataset:
P3779NT-proBNP adds incremental predictive information on incident atrial fibrillation in patients with asymptomatic aortic stenosis
Authors: Bang C N , Greve A M , Boman K , Egstrup K , Olsen M H , Kober L , Nienaber C A , Ray S , Rossebo A M , Nielsen O W , Willenheimer R , Wachtell K 
Published: October 2019

Abstract

Background
Incident atrial fibrillation (AF) marks an adverse shift in the prognosis of patients with aortic stenosis (AS). Identifying risk factors for AF is therefore of paramount importance for timely intervention in patients with AS. In patients without AS, brain natriuretic peptides (BNP) is a well-established biomarker for left ventricular pressure overload on the pathway to heart failure and atrial fibrillation. However, a potential role of NT-proBNP to predict risk of new-onset AF in asymptomatic patients with mild to moderate AS is not well studied.

Methods
We included 1,434 patients with mild to moderate AS from the SEAS Study (Simvastatin and Ezetimibe in Aortic Stenosis) without AF or clinically overt heart failure at baseline. The primary endpoint for this substudy was time to incident AF, as determined by the first annual in-study 12-lead ECG with AF. Multivariable Cox model were adjusted for other important predictors of incident AF as selected by Bayesian statistics. Fine and Gray competing risk regression was used to evaluate the influence of all-cause mortality on selected predictor variables of incident AF.

Results
During a median follow-up of 4.3 years (range 0.1–6.9 years), incident AF occurred in 114 (6.1%) patients (13.8 per 1,000 person-years of follow-up), who at baseline were older (69±10 vs. 67±10 years, p<0.001), had larger systolic left atrial diameter (46±24 vs. 34±18 mm, p<0.001) and higher NT-proBNP level (286 [132; 613] vs. 154 [82; 297] pg/ml, p<0.001); but same left ventricular ejection fraction (66±6 mm vs. 67±6, p=0.4). In multivariable Cox regression, adjusted for age, circumferential end-systolic stress, left atrial volume and ECG PR interval, Ln(NT-proBNP) was associated with higher risk of new-onset AF (HR: 1.9 [95% CI: 1.6–2.3], p<0.001). Similar results were found when using Fine and Gray estimates with all-cause mortality (HR: 2.0 [95% CI: 1.7–2.4], p<0.001 (Figure, panel A). NT-proBNP level added incremental predictive information on incident AF over the other important, as selected by Bayesian statistics, predictor variables (C-index 0.81, p<0.001, Figure, panel B). There was no interaction with aortic valve area (p>0.05).
Figure 1

Conclusions
In patients with asymptomatic aortic stenosis and sinus rhythm at baseline, NT-proBNP levels were significantly higher in patients who subsequently developed AF. NT-proBNP significantly improved prognostic information of incident AF over other important predictor variables. This supports the notion that incident AF is a marker of left ventricular pressure overload and possibly a novel marker of timely intervention with aortic valve replacement.
P3792The impact of elective cardioversion for atrial fibrillation in heart failure patients
Authors: Graby J , Carpenter A , Medland R , Brown S , Sowerby C , Priestman L , Dayer M , Furniss G 
Published: October 2019

Abstract

Introduction
Severe left ventricular systolic dysfunction (LVSD) is associated with worse outcomes in heart failure (HF) patients. Persistent atrial fibrillation (AF) is common in this patient group. As part of a nurse-led cardioversion service at a district general hospital we assessed the impact of elective cardioversion (DCCV) for AF in patients with LVSD on their ejection fraction (EF), and compared outcomes in patients selectively pre-treated with amiodarone for their DCCV.

Methods
A retrospective analysis was undertaken of DCCV for AF over 5 years, recording demographic, medication, serial echocardiogram (TTE), and outcome data. Significant LVSD was classified as moderate (ejection fraction [EF] 35–45%) or severe (EF<35%). All patients treated with amiodarone had baseline and serial thyroid, liver, renal function monitored, were counselled on side effects and followed up.

Results
103 patients with significant LVSD and follow-up TTE underwent DCCV, with a median age of 66 (IQR 58–73) and mean CHA2DS2-VASc 2.5. Overall mean baseline EF was 30% (SD ±11), overall follow-up EF (regardless of repeat TTE rhythm) was 42% (SD ±12), and the mean delta EF +12% improvement (SD ±11). At follow-up TTE, 66% (68/103) of patients were in sinus rhythm (SR) and 34% (35/103) in AF. 62/68 (91%) patients in SR at follow-up TTE were also treated with HF medications, vs 33/35 (94%) of those in AF. 61/68 (90%) of patients in SR at follow-up TTE had any improvement in EF vs 21/35 (60%) patients in AF (p=0.0007). For patients in SR the mean baseline EF was 31% (SD ±10) and mean follow-up EF 47% (SD ±9), vs the AF at repeat TTE patients' mean baseline EF 27% (SD ±12) and mean follow-up EF 35% (SD ±13). The mean delta EF of patients still in SR at follow-up scan was 15% (SD ±10) vs 8% (SD ±11) for patients who had reverted to AF (p=0.0004). Prior analysis of our data-set including patients awaiting repeat TTE demonstrated a significant improvement in 6 month AF recurrence rate.
Table 1. Comparing outcomes with amiodarone pre-treatment for patient with follow-up EF data Acute DCCV Success Mean Baseline EF Mean Repeat EF Mean Delta EF AF Recurrence to 6 months Amiodarone 17/17 (100%) 29% (SD 11) 45% (SD 11) 15% (SD 13) 6/17 (35%) No Amiodarone 80/86 (93%) 30% (SD 11) 42% (SD 12) 12% (SD 10) 50/86 (58%) P value 0.59 0.22 0.11

Conclusion
Restoration of SR in a cohort of patients with AF, severe LVSD, on good medical therapy significantly improves left ventricular EF. This reinforces the importance of maintaining SR for HF patients. There was also a trend towards improved medium term outcomes in patients pre-treated with amiodarone. Further study into long-term rhythm control and ablation outcomes is needed.
P3833Low heart rate variability is associated with future arrhythmic events in hypertension
Authors: Terentes-Printzios D , Vlachopoulos C , Korogiannis L , Christopoulou G , Xydis P , Ioakeimidis N , Aznaouridis K , Dima I , Georgakopoulos C , Tousoulis D 
Published: October 2019

Abstract

Background/Introduction
Cardiac autonomic dysfunction and target organ damage are associated with increased cardiovascular mortality and arrhythmias.

Purpose
The aim of the study was to investigate the effect of heart rate variability (HRV) and markers of target organ damage in the prognosis of future arrhythmic events.

Methods
We studied 292 untreated at baseline hypertensives (mean age 53±13, 153 males). Cardiac autonomic function was evaluated by analysis of short-term HRV measures over 24-h using 24-h ambulatory blood pressure monitoring and the standard deviation of the measurements. Echocardiography was also performed and left ventricular mass index (LVMI) was estimated with the Demereux formula. Aortic stiffness was assessed with carotid-femoral pulse wave velocity (cfPWV) and wave reflections with aortic augmentation index corrected for heart rate (Alx@75). Patients were followed up for a median period of 13 years. The primary endpoint was a composite of atrial/ventricular tachycardias, symptomatic multiple premature ventricular contractions, second and third-degree heart blocks and pacemaker/defibrillator placement.

Results
In comparison without events, patients with the primary endpoint (n=37, 13%) had lower 24-h daytime HRV (9.6 beats per minute vs. 11.1 beats per minute, p=0.005), higher systolic blood pressure (168 mmHg vs. 163 mmHg, p=0.003), higher cfPWV (8.4 m/s vs. 7.7 m/s, p=0.005), higher LVMI (133 g/m2 vs. 122 g/m2, p=0.002) and higher AIx@75 (29.0% vs. 26.3%, p=0.043). In further analysis, receiver operating characteristic (ROC) curves were generated to evaluate the ability of HRV, cfPWV, LVMI and AIx@75 to discriminate subjects with arrhythmic events. The area under the curve (AUC) and 95% CIs of the ROC curves were AUC=0.35 (95% CI: 0.26–0.44, p=0.003) for HRV, AUC=0.64 (95% CI: 0.54–0.73, P<0.006) for cfPWV, AUC=0.67 (95% CI: 0.58–0.75, P=0.001) for LVMI and AUC=0.55 (95% CI: 0.47–0.64, P=0.298) for AIx@75 (Figure). In Cox regression analysis, only HRV was associated with increased risk of arrhythmic events (Hazard ratio per 1 unit =0.87, 95% Confidence intervals 0.76 to 0.995, p=0.043) when adjusted for age, gender, cfPWV, LVMI and AIx@75.
ROC curves of HRV & target organ damage

Conclusions
Low heart rate variability is associated with increased risk of future arrhythmic events suggesting an early sympathovagal imbalance that could lead to future events in hypertension.
P3846The association between statin prescription, recurrent venous thromboembolism and bleeding events: from the COMMAND VTE Registry
Authors: Yoshikawa Y , Yamashita Y , Mabuchi H , Morimoto T , Amano H , Takase T , Hiramori S , Kim K , Oi M , Kobayashi Y , Toyofuku M , Tada T , Murata K , Sakamoto J , Kimura T 
Published: October 2019

Abstract

Background
Statin prevents occurrence and recurrence of atherosclerotic events. With regard to venous thromboembolism (VTE), a randomized controlled trial suggested that statin reduced occurrence of VTE, whereas its usefulness as secondary prevention of VTE remains to be elucidated.

Purpose
This study aimed to assess the association between statin prescription, recurrent VTE and bleeding events in patients with VTE.

Methods
The COMMAND VTE Registry is a multicentre registry enrolling consecutive 3027 patients with acute symptomatic VTE among 29 centres in Japan. We divided the cohort into the patients who were prescribed statin (N=437) and those not (N=2590), and compared the two groups. We assessed hazard ratios (HRs) of those with statin relative to those without for long-term clinical outcomes (recurrent symptomatic VTE and International Society of Thrombosis and Hemostasis [ISTH] major bleeding). Because the durations of anticoagulation therapy were widely different between the two groups, we constructed Cox's proportional hazard model incorporating status of anticoagulation during the follow-up period as a time-varying covariate. Also, because the incidences of death were strikingly different between the two groups due to the difference in the prevalence of active cancer, we used Fine-Gray's subdistribution hazard model in the presence of competing risks. We incorporated clinically relevant factors into these two models as covariates (10 factors for recurrent VTE and 11 for major bleeding).

Results
The statin group was significantly older than the non-statin group (statin 71.2±11.8 vs. non-statin 66.5±15.8, P<0.001). The prevalence of active cancer in the statin group was less than one-half of that in the non-statin group (12% vs. 25%, P<0.001), and the cumulative 3-year incidence of death was significantly lower in the statin group than in the non-statin group (12.8% vs. 26.1%, log-rank P<0.001). The table shows the adjusted HRs of the statin group relative to the non-statin group. The HRs of the statin group relative to non-statin group for recurrent VTE were significantly low, but those for major bleeding were insignificant.
Adjusted hazard ratios Outcome measures Model 1 P value Model 2 P value Adjusted HR [95% CI] Adjusted HR [95% CI] Recurrent VTE 0.59 [0.36–0.98] 0.042 0.53 [0.32–0.89] 0.02 Major bleeding 0.87 [0.60–1.24] 0.43 0.997 [0.69–1.43] 0.99 Model 1 derived from Cox's model with time-varying covariate of anticoagulation status. Model 2 derived from Fine-Gray's model.
Study flowchart

Conclusions
Prescription of satin was associated with significantly low risks for recurrent VTE, whereas that was not for major bleeding events. Statin could be a potential treatment option for secondary prevention of VTE.
P3849Baseline profile of patients treated for acute venous thromboembolism in routine clinical practice according to age and renal function in the RE-COVERY DVT/PE global cohort study
Authors: Ageno W , Casella I B , Han C K , Schellong S , Schulman S , Singer D E , Desch M , Tang W , Voccia I , Zint K , Goldhaber S Z 
Published: October 2019

Abstract

Background
Observational studies provide the opportunity to evaluate routine practice without the selection and treatment criteria imposed in randomized clinical trials (RCTs).

Purpose
Using data from the RE-COVERY DVT/PE global observational study (enrolment January 2016 to May 2017), we describe the baseline profile of patients treated for acute venous thromboembolism (VTE) in routine clinical practice according to age and renal function.

Methods
Baseline patient characteristics, clinical features (comorbidities/medical history), and anticoagulant therapy were tabulated descriptively for the subgroups of age (<75, ≥75 years) and creatinine clearance (<30, 30 to <50 [moderate impairment], 50 to <80 [mild impairment], ≥80 mL/min). Anticoagulant therapy at baseline and at hospital discharge or 14 days after diagnosis (whichever was later) was recorded.

Results
In this observational study of 6122 patients with acute deep vein thrombosis, the proportions of patients at baseline who were ≥75 years of age (25.2%) or who had mild to moderate renal impairment (38.1%) were higher than in RCTs of non-vitamin K antagonist oral anticoagulants (NOACs) for acute VTE treatment (∼12–13% elderly and ∼26–29% with mild or moderate renal impairment) (from analyses of the RE-COVER trials; Hokusai-VTE and AMPLIFY). Older patients and those with renal impairment were more often female and were more likely to have comorbidities than the younger or normal renal function groups (Table). At the time of hospital discharge or 14 days after diagnosis, whichever was later, the majority was treated with NOACs (54%). Vitamin K antagonists were prescribed to approximately 1 in 5 patients. The use of NOACs decreased with worsening renal function, whereas the proportions treated with parenteral anticoagulation alone increased in the moderate renal impairment group compared with patients with normal renal function.

Conclusion
The population treated for acute VTE in routine clinical practice includes more elderly and renally impaired patients than represented in RCTs. These baseline data provide a snapshot of patient characteristics and patterns of anticoagulant therapy.

Acknowledgement/Funding
Funded by Boehringer Ingelheim
P3859Stroke after transcatheter aortic valve implantation: an unpredictable risk?
Authors: Maier O , Bosbach G , Hellhammer K , Zeus T , Kelm M , Veulemans V 
Published: October 2019

Abstract

Background
Transcatheter aortic valve implantation (TAVI) has become the preferred alternative to surgical valve replacement in high risk patients with severe symptomatic aortic stenosis. Stroke is still a feared complication following TAVI, associated with increased mortality and severe impact on patients' daily living. Despite technological development and knowledge improvement, cerebrovascular events (CVE) are still not predictable so far and simple risk scores are lacking. The expansion of TAVI therapy towards younger and lower risk populations will force us to discover the mechanisms determining stroke after TAVI.

Purpose
This study aimed to evaluate different patient and procedure related factors for prediction of stroke after TAVI, especially regarding severity of aortic calcification.

Methods
From May 2011 to January 2018 a total of 1365 patients underwent TAVI with a balloon-expandable (32.4%) or self-expandable (67.6%) valve at our institution. 60 patients (4.4%) suffered from new neurological impairment in terms of CVE after TAVI during hospital stay (mean 11.2±6.7 days). We performed propensity score matching (1:10) to balance baseline characteristics between patients with and without stroke following TAVI, resulting in 56 patients with in-hospital stroke and 521 patients without neurological disorder. Stroke was defined according to the Valve Academic Research Consortium recommendations (VARC-2).

Results
Body surface area (stroke vs. control: 2.73±0.27 vs. 2.81±0.29 m2; p=0.0451) and prior stroke (stroke vs. control: 17.86% vs. 8.64%; p=0.0256) were patient related predictors of stroke after TAVI during in-hospital stay. While aortic valve Agatston score (stroke vs. control: 2475±1593 vs. 2060±1344 AU; p=0.0383) and ascending thoracic aorta Agatston score (stroke vs. control: 986.5±1989 vs. 505.2±1018 AU; p=0.0045) showed to be good predictors, peripheral vascular diseases were not associated with stroke (stroke vs. control: 35.7% vs. 31.3%; p=0.4986). A procedural predictor of acute CVE was extended procedure time (stroke vs. control: 101.8±39.6 vs. 90.0±31.3 hours; p=0.0105). Finally, stroke after TAVI resulted in clearly prolonged hospital stay (stroke vs. control: 16.1±9.0 vs. 10.7±6.2 days; p<0.0001).

Conclusion
The severity of aortic valve and ascending thoracic aorta calcification predicts stroke after TAVI as well as extended procedure time, possibly due to increased mechanical intravascular manipulation by prolonged catheterisation. These correlations could guide us in identifying those patients who are most likely to benefit from transcatheter cerebral embolic protection devices.
P4126Safety of magnetic resonance imaging in patients with non-conditional cardiac implantable electronic devices: A systematic review and meta-analysis
Authors: Padmanabhan D , Farwati M , Izath A , Al-Masry A , Kella D , Gamero S , Barout A , Assaf Y , Shetty D , Asirvatham S , Felmlee J , Watson R , Cha Y.-M , Friedman P 
Published: October 2019

Abstract

Recent guideline statements approve the performance of magnetic resonance imaging (MRI) in patients with non-conditional cardiac implantable electronic devices (CIEDs) under certain closely monitored conditions. Data from current registries may have lower power to discern changes that may occur in the CIED after the MRI.

Objective
We aimed to systematically review the literature to identify the adverse events and significance of changes in device function associated with performing MRI in patients with CIEDs

Methods
A comprehensive literature search of the databases was performed between 1980- 2017. Two independent reviewers selected studies and extracted data. A random-effects model was used for meta-analysis.

Results
A total of 7,422 patients underwent 8,865 MRI studies. No death occurred post MRI. Clinical adverse events were extremely rare (mostly less than 1%) and are summarized in Table 1. No significant changes in the pooled mean effect size estimate was noted for the changes in the lead parameters (pacing threshold, sensing and impedance)
Binary outcomes post magnetic resonance imaging in patients with non-conditional cardiac implantable electronic devices Outcome Sample size Number of patients Rate SE LL of CI UL of CI Death 7401 0 0 0 0 0 Atrial arrhythmia 7173 10 0.001 0.0004 0.0007 0.0024 Ventricular arrhythmia 7371 9 0.0012 0.0004 0.0006 0.0022 Oversensing 4981 17 0.0034 0.0008 0.0020 0.0053 Inhibition of pacing 7371 6 0.0008 0.0003 0.0003 0.0016 Lead Failure/Generator Failure 7475/7475 2/8 0.0002/0.0011 0.0001/0.0004 0.0001/0.0005 0.0009/0.002 Power on Reset 1388 105 0.0131 0.0014 0.0107 0.0161 Did not complete scan 6851 13 0.0019 0.0005 0.0011 0.0031 Chest pain 7080 11 0.0021 0.0004 0.0008 0.0027. Lead threshold rise (>0.5v/>50%-A/V) 5076/6246 12/16 0.0024/0.0026 0.0007/0.0006 0.0013/0.0015 0.0040/0.0041 Change in Battery voltage >0.04V 7132 42 0.0061 0.0009 0.0043 0.0079 Sensing decrease >50%-A/V 5087/5834 17/9 0.0033/0.0015 0.0008/0.0005 0.0020/0.0008 0.0052/0.0028 Impedance changes >50ohms/>50% 5810 22 0.0038 0.0008 0.0024 0.0057 Rise in cardiac enzymes 1703 26 0.0152 0.0030 0.0102 0.0219 A, atrial; V, ventricular; SE, standard Error; LL, lower limit; UL, upper limit; CI, Confidence intervals.

Conclusions
MRI in patients with non-conditional CIEDs can be performed with high degree of safety and low rate of clinical events when performed under standardized protocols

Acknowledgement/Funding
None
P4130Age-related changes in pulmonary artery flow measured by non-invasive cardiac magnetic resonance imaging
Authors: Agoston Vas Coldea L N , Muresan I , Mocan T 
Published: October 2019

Abstract

Background
Ageing, a major cardiovascular risk factor, is associated with increased arterial stiffness. The evaluation of physiological changes of the pulmonary artery (PA) wall in healthy subjects of different ages may be relevant in clinical practice. The aim of the present study was to investigate age-related changes of PA flow and elasticity by phase-contrast cardiovascular magnetic resonance (PC-CMR) in a population of patients without cardiovascular disease.

Methods
Nightly, apparently healthy subjects (20 to 70 years old, 58 males), underwent velocity-encoded CMR of the PA using a 1.5T system. The assessment of the PA flow and the arterial stiffness, using phase-contrast cardiovascular magnetic resonance (PC-CMR), was made non-invasively, by subtracting simultaneous forward flow and reversed flow velocity in the main PA. Data were divided in 2 groups, one with the subjects <45 years and the other >45 years. Comparisons were made between the young one (≤45 years, n=49) and the older subjects (>45 years, n=41).

Results
PA area increased significantly with age. Reversed flow volume and peak velocity also increased; the time until the start of reversed flow was shortened as age increased (p<0.01), while global flow and forward flow parameters remained unchanged. Ratio of peak velocity reversed flow to forward flow was strongly related to both age and arterial stiffness. A multivariate analysis was performed, in order to establish the correlation between PA stiffness and reversed flow parameters, adjusted for age, gender and body surface area. The independent variables of the peak velocity reversed flow reversed flow were age, PA diameter, right ventricular ejection fraction and right ventricular mass.

Conclusion
PA reversed flow parameters, including peak velocity flow and volume, measured by PC-CMR, increase significantly and show up earlier with ageing. Therefore, this assessment could be used in finding relevant markers of subclinical vascular aging.